Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.

Mancia G, Schumacher H, Böhm M, Redon J, Schmieder RE, Verdecchia P, Sleight P, Teo K, Yusuf S.

Hypertension. 2017 Nov;70(5):938-948. doi: 10.1161/HYPERTENSIONAHA.117.09714. Epub 2017 Oct 3.

PMID:
28974567
2.

Music and the heart.

Sleight P.

Eur Heart J. 2015 Sep 14;36(35):2347. No abstract available.

PMID:
26623470
3.

Music and the heart.

Sleight P.

Eur Heart J. 2015 Jul 21;36(28):1786.

PMID:
26413596
4.

Healthy eating and reduced risk of cognitive decline: A cohort from 40 countries.

Smyth A, Dehghan M, O'Donnell M, Anderson C, Teo K, Gao P, Sleight P, Dagenais G, Probstfield JL, Mente A, Yusuf S; ONTARGET and TRANSCEND Investigators.

Neurology. 2015 Jun 2;84(22):2258-65. doi: 10.1212/WNL.0000000000001638. Epub 2015 May 6.

5.

Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.

Böhm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S.

Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12.

PMID:
25583157
6.

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A.

Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9.

PMID:
25579834
7.

Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.

Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S.

Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20.

PMID:
25331850
8.

A historical perspective on peripheral reflex cardiovascular control from animals to man.

Sleight P.

Exp Physiol. 2014 Aug;99(8):1017-26. doi: 10.1113/expphysiol.2014.079434. Epub 2014 Jul 1. Review.

9.

Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.

Foulquier S, Böhm M, Schmieder R, Sleight P, Teo K, Yusuf S, Schumacher H, Unger T.

J Hypertens. 2014 Jun;32(6):1334-41. doi: 10.1097/HJH.0000000000000154.

PMID:
24621807
10.

2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology.

Blood Press. 2014 Feb;23(1):3-16. doi: 10.3109/08037051.2014.868629. Epub 2013 Dec 20. No abstract available.

PMID:
24359485
11.

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.

Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.

PMID:
24191305
12.

Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.

Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S.

Am Heart J. 2013 Aug;166(2):306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Epub 2013 Jun 24.

PMID:
23895814
13.

Blood pressure levels for treatment of uncomplicated diabetes in primary care.

Sleight P.

J Hypertens. 2013 Aug;31(8):1527-8. doi: 10.1097/HJH.0b013e328362ff43. No abstract available.

PMID:
23822923
14.

Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients.

Kratz MT, Schumacher H, Sliwa K, Schmieder R, Pöss J, Mahfoud F, Unger T, Lonn E, Koon T, Mancia G, Sleight P, Yusuf S, Böhm M.

Eur J Prev Cardiol. 2014 Mar;21(3):272-80. doi: 10.1177/2047487313494835. Epub 2013 Jul 1. Erratum in: Eur J Prev Cardiol. 2015 Jul;22(7):950.

PMID:
23818288
15.

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members.

J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc. No abstract available.

PMID:
23817082
16.

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA.

Eur Heart J. 2013 Jul;34(28):2159-219. doi: 10.1093/eurheartj/eht151. Epub 2013 Jun 14. No abstract available.

PMID:
23771844
17.

Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.

Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Rydén L, Sleight P, Teo KK, Yusuf S; ONTARGET investigators.

J Hypertens. 2013 Feb;31(2):414-21. doi: 10.1097/HJH.0b013e32835bf7b0.

PMID:
23249829
18.

Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.

Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators.

Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234.

PMID:
23212996
19.

Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.

Barzilay JI, Gao P, Clase CM, Mente A, Mann JF, Sleight P, Yusuf S, Teo KK; OnTARGET/TRANSCEND Investigators.

Clin J Am Soc Nephrol. 2013 Feb;8(2):233-40. doi: 10.2215/CJN.06640712. Epub 2012 Nov 26.

20.

Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).

Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon J, Czuriga I, Polák M, Ribeiro JM, Sanchez R, Trimarco B, Verdecchia P, van Mieghem W, Teo K, Sleight P, Yusuf S.

Hypertension. 2012 Dec;60(6):1400-6. doi: 10.1161/HYPERTENSIONAHA.112.199562. Epub 2012 Oct 15.

PMID:
23071122
21.

Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease.

Liang Y, Mente A, Yusuf S, Gao P, Sleight P, Zhu J, Fagard R, Lonn E, Teo KK; ONTARGET and TRANSCEND Investigators.

CMAJ. 2012 Nov 6;184(16):E857-66. doi: 10.1503/cmaj.120412. Epub 2012 Oct 1.

22.

Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).

Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators.

Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24.

PMID:
22829023
23.

Nonpharmacological treatments for hypertension.

Sleight P.

J Hypertens. 2012 Aug;30(8):1516-7. doi: 10.1097/HJH.0b013e328356d99c. No abstract available.

PMID:
22785233
24.

Influenza vaccination and major adverse vascular events in high-risk patients.

Johnstone J, Loeb M, Teo KK, Gao P, Dyal L, Liu L, Avezum A, Cardona-Munoz E, Sleight P, Fagard R, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial (ONTARGET); Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators.

Circulation. 2012 Jul 17;126(3):278-86. doi: 10.1161/CIRCULATIONAHA.111.071100. Epub 2012 Jun 19.

PMID:
22715472
25.

Cognitive impairment and risk of cardiovascular events and mortality.

O'Donnell M, Teo K, Gao P, Anderson C, Sleight P, Dans A, Marzona I, Bosch J, Probstfield J, Yusuf S.

Eur Heart J. 2012 Jul;33(14):1777-86. doi: 10.1093/eurheartj/ehs053. Epub 2012 May 2.

PMID:
22551598
26.

Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.

Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators.

J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.

PMID:
22495138
27.

Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

Zannad F, Stough WG, Pocock SJ, Sleight P, Cushman WC, Cleland JG, McMurray JJ, Lonn E, Geller NL, Wedel H, Abadie E, Alonso-Garcia A, Pitt B.

Eur Heart J. 2012 May;33(9):1049-57. doi: 10.1093/eurheartj/ehr437. Epub 2012 Mar 15. Review.

PMID:
22422830
28.

Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators.

J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.

29.

Urinary sodium and potassium excretion and risk of cardiovascular events.

O'Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, McQueen M, Sleight P, Sharma AM, Dans A, Probstfield J, Schmieder RE.

JAMA. 2011 Nov 23;306(20):2229-38. doi: 10.1001/jama.2011.1729.

PMID:
22110105
30.

Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).

Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S.

Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26.

PMID:
21947289
31.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators.

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

32.

Clinical and haemodynamic correlates of heart rate turbulence as a non-invasive index of baroreflex sensitivity in chronic heart failure.

La Rovere MT, Maestri R, Pinna GD, Sleight P, Febo O.

Clin Sci (Lond). 2011 Sep;121(6):279-84. doi: 10.1042/CS20110063.

33.

Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome.

Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, Textor S, Sleight P.

Eur Heart J. 2011 Sep;32(18):2231-5. doi: 10.1093/eurheartj/ehr056. Epub 2011 Mar 15. No abstract available.

PMID:
21406441
34.

Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R.

JAMA. 2010 Jun 23;303(24):2486-94. doi: 10.1001/jama.2010.840.

PMID:
20571015
35.

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.

Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators.

Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15.

PMID:
20231536
36.

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators.

Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21.

PMID:
19770395
37.

Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.

Sleight P.

J Hypertens Suppl. 2009 Jul;27(5):S23-9. doi: 10.1097/01.hjh.0000357905.78704.9a.

PMID:
19587551
38.

Dynamic interactions between musical, cardiovascular, and cerebral rhythms in humans.

Bernardi L, Porta C, Casucci G, Balsamo R, Bernardi NF, Fogari R, Sleight P.

Circulation. 2009 Jun 30;119(25):3171-80.

PMID:
19569263
39.

The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.

Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, Whitlock G, Clark S, Youngman L, Sleight P, Collins R; International Studies of Infarct Survival Collaborators.

Eur Heart J. 2009 Sep;30(17):2137-46. doi: 10.1093/eurheartj/ehp221. Epub 2009 Jun 11.

40.

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.

Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators.

J Hypertens. 2009 Jul;27(7):1360-9. doi: 10.1097/HJH.0b013e32832d7370.

PMID:
19506526
41.

Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure).

Mortara A, Pinna GD, Johnson P, Maestri R, Capomolla S, La Rovere MT, Ponikowski P, Tavazzi L, Sleight P; HHH Investigators.

Eur J Heart Fail. 2009 Mar;11(3):312-8. doi: 10.1093/eurjhf/hfp022.

42.

Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients.

Pinna GD, Maestri R, Mortara A, Johnson P, Andrews D, Ponikowski P, Witkowski T, Robbi E, La Rovere MT, Sleight P.

Eur J Heart Fail. 2009 Mar;11(3):264-72. doi: 10.1093/eurjhf/hfp006. Epub 2009 Feb 3.

43.

Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.

Cukierman-Yaffe T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L, Jackson SH, Yusuf S, Teo K; ONTARGET/TRANSCEND Investigators.

Diabetes Res Clin Pract. 2009 Mar;83(3):387-93. doi: 10.1016/j.diabres.2008.12.005. Epub 2009 Jan 20.

PMID:
19157618
44.

Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era.

La Rovere MT, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, Sleight P, Febo O.

J Am Coll Cardiol. 2009 Jan 13;53(2):193-9. doi: 10.1016/j.jacc.2008.09.034.

45.

Cardiovascular protection for all individuals at high risk: evidence-based best practice.

Bakris G, Böhm M, Dagenais G, Diener HC, Fujita T, Gorelick P, Kjeldsen SE, Laakso M, Mancia G, Pitt B, Sharma A, Sleight P, Teo K, Unger T, Weber M, Williams B, Zannad F.

Clin Res Cardiol. 2008 Oct;97(10):713-25. doi: 10.1007/s00392-008-0713-2. Epub 2008 Aug 23. Review.

PMID:
18726243
46.

Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.

Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ; INVEST Investigators.

Am Heart J. 2008 Aug;156(2):241-7. doi: 10.1016/j.ahj.2008.02.023.

PMID:
18657652
47.

No HOPE without proof: do ARBs meet the standard for cardiovascular protection?

Sleight P, Jakobsen A, Heroys J, Ralph A, Rees T, Shaw M.

Medscape J Med. 2008 Mar 26;10 Suppl:S6. Review.

48.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.

49.

Specific barriers to the conduct of randomized trials.

Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, Chrolavicius S, Li T, Ounpuu S, Perez AC, Sleight P, Svard R, Temple R, Tsouderous Y, Yunis C, Yusuf S.

Clin Trials. 2008;5(1):40-8. doi: 10.1177/1740774507087704.

PMID:
18283079
50.

New methods for risk stratification in patients after myocardial infarction autonomic control and substrate sensitivity.

Sleight P.

J Am Coll Cardiol. 2007 Dec 11;50(24):2291-3. Epub 2007 Nov 26. No abstract available.

Supplemental Content

Loading ...
Support Center